Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AstraZeneca PLC (AZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. AstraZeneca files under Form 20-F for its annual report and uses Form 6-K to furnish current reports on material developments. These filings cover a broad range of topics, including clinical trial data, regulatory approvals, manufacturing investments, insider share transactions and changes in major shareholdings.
For investors following AstraZeneca’s oncology franchise, 6-K exhibits often reproduce detailed press releases on medicines such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan) and Imfinzi (durvalumab). These documents describe Phase 3 trial designs and endpoints, Breakthrough Therapy Designations, new indications in breast, lung, gastric, endometrial and ovarian cancers, and approvals in key markets. They can help readers understand how specific trials, such as DESTINY-Breast, TROPION, MATTERHORN and others, relate to AstraZeneca’s pipeline and commercial portfolio.
Filings also address Rare Diseases and Respiratory & Immunology, including updates on Koselugo (selumetinib) for neurofibromatosis type 1 and Saphnelo (anifrolumab) for systemic lupus erythematosus. Additional 6-Ks report on large capital projects, such as multi‑billion‑dollar manufacturing investments in Maryland and other US states, and on governance matters like director and senior executive share dealings or notifications of major institutional holdings.
On Stock Titan, these AZN filings are supplemented with AI-powered summaries that explain the key points of each document in plain language. Users can quickly see which filings relate to new indications, safety information, insider transactions (similar to Form 4-style disclosures for US issuers) or strategic investments. Real-time updates from EDGAR ensure that new AstraZeneca 6-Ks and other SEC submissions appear promptly, while AI insights help readers navigate lengthy technical exhibits such as clinical trial descriptions and multi-indication product updates.
AstraZeneca PLC reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been approved in the EU as the first perioperative immunotherapy for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen is given before and after surgery, then continued as Imfinzi alone.
The approval is based on the Phase III MATTERHORN trial, where Imfinzi plus FLOT cut the risk of disease progression, recurrence or death by 29% (event-free survival HR 0.71; p<0.001) versus chemotherapy alone, with higher one- and two-year event-free rates. Final overall survival data showed a 22% reduction in the risk of death (HR 0.78; p=0.021), with an estimated 69% of patients alive at three years compared with 62% on chemotherapy alone. The safety profile and surgery completion rates were similar between arms.
AstraZeneca PLC has published its Notice of Annual General Meeting 2026 and shareholders’ circular and is dispatching them to shareholders. The digitally-enabled AGM will be held on 9 April 2026 at 14:30 (BST).
Shareholders will vote on receiving the 2025 accounts, confirming 2025 interim dividends, appointing KPMG LLP as auditor, re-electing directors, approving the remuneration report, renewing authority for the 2020 Performance Share Plan French appendix, authorising political donations, allotting shares, disapplying pre-emption rights, authorising share buybacks, and reducing the notice period for general meetings. The Notice and related documents are available on AstraZeneca’s website and via the UK National Storage Mechanism.
AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).
The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.
AstraZeneca PLC reported that share awards granted under its AstraZeneca Deferred Bonus Plan for 2022 performance vested on 4 March 2026 for senior executives. These awards reflect portions of prior annual bonuses that were deferred into ordinary shares and held for a three-year period.
On vesting, Chief Executive Officer Pascal Soriot acquired 14,967 ordinary shares and Chief Financial Officer Aradhana Sarin acquired 4,863 ordinary shares, both for nil consideration. For tax purposes, the fair market value at vest was 14,932 pence per ordinary share, based on the closing price on the last trading day before vesting.
AstraZeneca PLC reported that on 4 March 2026 it granted share awards to its Chief Executive Officer and Chief Financial Officer under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan.
Pascal Soriot received 13,970 Ordinary Shares under the deferred bonus plan and 89,611 under the performance share plan, at an award price of £152.42 per share. Aradhana Sarin received 5,258 Ordinary Shares under the deferred bonus plan and 37,135 under the performance share plan, also at £152.42 per share.
The deferred bonus awards represent required deferrals of each executive’s 2025 annual bonus into shares and are due to vest after a three-year holding period. The performance share awards are subject to scientific, commercial, financial and sustainability performance measures assessed from 1 January 2026 to 31 December 2028 and then a further two-year holding period, vesting on the fifth anniversary of grant.
AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.
The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.
AstraZeneca PLC reports its current voting share capital. As at 28 February 2026, the company has 1,550,966,708 issued ordinary shares of US$0.25 each with voting rights, and no shares held in treasury. This means the total number of voting rights is 1,550,966,708.
Shareholders can use this total voting rights figure as the denominator when calculating whether they must notify the UK Financial Conduct Authority of holdings or changes in their interest under the Disclosure and Transparency Rules.
AstraZeneca PLC has priced a $2bn global bond offering through its wholly owned subsidiary AstraZeneca Finance LLC. The bonds are issued in three fixed-rate tranches registered with the U.S. SEC and are fully and unconditionally guaranteed by AstraZeneca.
The tranches comprise $0.65bn of notes with a 4.000% coupon maturing on 2 March 2031, $0.60bn with a 4.300% coupon maturing on 2 March 2033, and $0.75bn with a 4.600% coupon maturing on 2 March 2036.
AstraZeneca expects to use the net proceeds for general corporate purposes, which may include refinancing existing debt. The company states that this bond issuance does not impact its financial guidance for 2026.